Quick Answer
Jade Biosciences, Inc. reported Net Income Loss of -$127.41 million for the year ending 2025.
- Jade Biosciences, Inc. showed a decrease of -83.0% in Net Income Loss from 2024 to 2025.
- This data is from Jade Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$1.44 million | Q2 2020: -$2.20 million | Q3 2020: -$2.31 million | Q1 2021: -$2.78 million | Q2 2021: -$5.78 million | Q3 2021: -$6.18 million | Q1 2022: -$10.91 million | Q2 2022: -$11.99 million | Q3 2022: -$13.59 million | Q1 2023: -$16.52 million | Q2 2023: -$19.03 million | Q3 2023: -$19.56 million | Q1 2024: -$23.19 million | Q2 2024: -$24.78 million | Q2 2024: -$590.0 thousand | Q3 2024: -$16.28 million | Q1 2025: -$38.17 million | Q2 2025: -$32.13 million | Q3 2025: -$25.18 million.
- Over the full 6 years of available data (2020 to 2025), Jade Biosciences, Inc.'s Net Income Loss has declined by 1,225.7%.
- Historical annual values: Fiscal year 2025: -$127.41 million | Fiscal year 2024: -$69.63 million | Fiscal year 2023: -$75.52 million | Fiscal year 2022: -$51.51 million | Fiscal year 2021: -$22.96 million | Fiscal year 2020: -$9.61 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: